Long-term use of aspirin may reduce risk for pancreatic cancer

Continual use of low-dose or regular-dose aspirin may cut a person’s risk of developing pancreatic cancer in half, a Yale School of Public Health and Yale Cancer Center study has found. Further, the degree of protection may grow the longer one takes the aspirin. The Yale researchers collected data from a Connecticut population study of 362 newly diagnosed pancreatic cancer patients and a control group of 690 disease-free people. They analyzed associations between risk of pancreatic cancer and past aspirin use. Read more here.